I was looking at this stock as a potential buy opportunity.
My conclusion - I would consider buying this stock if the website didn't have so many typos, half-truth medical information, and sound like someone who didn't speak English wrote the entire thing without adequate editing.
IF any significant investor visits the site they will be turned away by the lack of professionalism.
By the way, what exactly is in Control 24?
IT might work in Korea, or with the uninformed, but not here.